Ionis delays prion disease readout; Arvinas’ Parkinson’s biomarker datanews2026-03-18T14:17:05+00:00March 18th, 2026|Endpoints News|
FDA approves J&J’s psoriasis pill Icotyde with $5B+ peak sales potentialnews2026-03-18T13:39:56+00:00March 18th, 2026|Endpoints News|
Briggs Morrison’s Crossbow unveils $77M Series B for T cell engagersnews2026-03-18T13:02:40+00:00March 18th, 2026|Endpoints News|
Aspen’s personalized Parkinson’s therapy shows early promisenews2026-03-18T13:00:44+00:00March 18th, 2026|Endpoints News|
Shanghai biotech Excalipoint gains $68.7M for T cell engagersnews2026-03-18T12:00:09+00:00March 18th, 2026|Endpoints News|
Xaira unveils AI model X-Cell for predicting virtual cellsnews2026-03-18T10:00:04+00:00March 18th, 2026|Endpoints News|
CMS innovation center to expand team focused on drug pricesnews2026-03-17T19:07:25+00:00March 17th, 2026|Endpoints News|
Aldeyra dry eye drug gets third rejection from FDA, triggering stock slidenews2026-03-17T18:30:14+00:00March 17th, 2026|Endpoints News|
Drugmakers consider licensing deal tweaks to soften MFN impactnews2026-03-17T16:47:55+00:00March 17th, 2026|Endpoints News|
Karen Weintraub and Kevin Miller to join Endpoints News as editorsnews2026-03-17T16:30:06+00:00March 17th, 2026|Endpoints News|
